Aktis Oncology (AKTS) vs Cullinan Therapeutics (CGEM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Aktis Oncology is the larger company by market cap ($986.7 million vs $950.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKTS | CGEM |
|---|---|---|
| Share price | $17.74 | $15.46 |
| Market cap | $986.69M | $950.14M |
| 1-day change | -1.44% | -1.09% |
| YTD return | — | +51.01% |
| 1-year return | — | +165.37% |
| 5-year return | — | -37.48% |
| EPS (TTM) | $-1.70 | $-3.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $34.19 | $23.19 |
| 52-week low | $14.72 | $6.50 |
| Distance from 52-week high | -48.11% | -33.33% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +99.49% | +116.36% |
| Average volume | 364.04K | 871.08K |
| Shares outstanding | 53.75M | 61.46M |
| Employees | 79 | 109 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aktis Oncology
AKTS stock →Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 79 employees
About Cullinan Therapeutics
CGEM stock →Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 109 employees
AKTS vs CGEM FAQ
Which is bigger, Aktis Oncology or Cullinan Therapeutics?
Aktis Oncology (AKTS) is larger, with a market capitalization of $986.69M compared with $950.14M for Cullinan Therapeutics (CGEM).
Are Aktis Oncology and Cullinan Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Aktis Oncology and Biotechnology: Biological Products (No Diagnostic Substances) for Cullinan Therapeutics.